No inhibitory effect on P-glycoprotein function at blood-brain barrier by clinical dose of clarithromycin: A human PET study with [11C] verapamil

Annals of Nuclear Medicine

Volumn 24, Issue 2, 2010, Pages 83-87

  Arakawa, Ryosuke ^a   Ito, Hiroshi ^a   Okumura, Masaki ^a   Morimoto, Takuya ^a   Seki, Chie ^a   Takahashi, Hidehiko ^a   Takano, Akihiro ^a   Suhara, Tetsuya ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

11C Verapamil; Blood brain barrier; Clarithromycin; P glycoprotein; Positron emission tomography

Indexed keywords

CLARITHROMYCIN; GLYCOPROTEIN P; NORVERAPAMIL; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VERAPAMIL; VERAPAMIL C 11;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; DRUG EFFECT; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; STATISTICAL ANALYSIS;

ADULT; ANTI-BACTERIAL AGENTS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CARBON RADIOISOTOPES; CLARITHROMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; P-GLYCOPROTEIN; POSITRON-EMISSION TOMOGRAPHY; VERAPAMIL; YOUNG ADULT;

EID: 77950689096     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12149-009-0336-3     Document Type: Article

References (25)

1. Chinn LW, Kroetz DL. ABCB1 pharmacogenetics: progress, pitfalls, and promise. Clin Pharmacol Ther. 2007;81:265-269
2. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene. 2003;22:7468-7485 (Pubitemid 37487170)
3. Linnet K, Ejsing TB. A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. Eur Neuropsychopharmacol. 2008;18:157-169
4. Liu X, Chen C, Smith BJ. Progress in brain penetration evaluation in drug discovery and development. J Pharmacol Exp Ther. 2008;325:349-356 (Pubitemid 351574780)
5. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther. 2000;68:231-237
6. Troger U, Lins H, Scherrmann JM, Wallesch CW, Bode-Boger SM. Tetraparesis associated with colchicine is probably due to inhibition by verapamil of the P-glycoprotein efflux pump in the blood-brain barrier. BMJ. 2005;331:613. (Pubitemid 41360773)
7. Fenner KS, Troutman MD, Kempshall S, Cook JA, Ware JA, Smith DA, et al. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther. 2009;85:173-181
8. Ikoma Y, Takano A, Ito H, Kusuhara H, Sugiyama Y, Arakawa R, et al. Quantitative analysis of 11C-verapamil transfer at the human blood-brain barrier for evaluation of P-glycoprotein function. J Nucl Med. 2006;47:1531-1537 (Pubitemid 47544942)
9. Brunner M, Langer O, Sunder-Plassmann R, Dobrozemsky G, Muller U, Wadsak W, et al. Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin Pharmacol Ther. 2005;78:182-190 (Pubitemid 41112286)
10. Takano A, Kusuhara H, Suhara T, Ieiri I, Morimoto T, Lee YJ, et al. Evaluation of in vivo P-glycoprotein function at the bloodbrain barrier among MDR1 gene polymorphisms by using 11C-verapamil. J Nucl Med. 2006;47:1427-1433 (Pubitemid 47544927)
11. Kortekaas R, Leenders KL, van Oostrom JC, Vaalburg W, Bart J, Willemsen AT, et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol. 2005;57:176-179 (Pubitemid 40179854)
12. Bartels AL, Willemsen AT, Kortekaas R, de Jong BM, de Vries R, de Klerk O, et al. Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. J Neural Transm. 2008;115:1001-1009
13. Bartels AL, van Berckel BN, Lubberink M, Luurtsema G, Lammertsma AA, Leenders KL. Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease. Parkinsonism Relat Disord. 2008;14:505-508
14. Langer O, Bauer M, Hammers A, Karch R, Pataraia E, Koepp MJ, et al. Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[11C]verapamil. Epilepsia. 2007;48:1774-1784 (Pubitemid 47352863)
15. Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, et al. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther. 2005;77:503-514 (Pubitemid 40824964)
16. Lee YJ, Maeda J, Kusuhara H, Okauchi T, Inaji M, Nagai Y, et al. In vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using [11C]verapamil. J Pharmacol Exp Ther. 2006; 316:647-653 (Pubitemid 43130991)
17. Wang L, Kitaichi K, Hui CS, Takagi K, Sakai M, Yokogawa K, et al. Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo. Clin Exp Pharmacol Physiol. 2000;27:587-593 (Pubitemid 30436195)
18. Zhang L, Liu XD, Xie L, Wang GJ. P-glycoprotein restricted transport of nimodipine across blood-brain barrier. Acta Pharmacol Sin. 2003;24:903-906 (Pubitemid 37081793)
19. Wegman TD, Maas B, Elsinga PH, Vaalburg W. An improved method for the preparation of [11C]verapamil. Appl Radiat Isot. 2002;57:505-507
20. Alvarez-Elcoro S, Enzler MJ. The macrolides: erythromycin, clarithromycin, and azithromycin. Mayo Clin Proc. 1999;74:613-634 (Pubitemid 29264782)
21. Jain R, Danziger LH. The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview. Curr Pharm Des. 2004;10:3045-3053 (Pubitemid 39242900)
22. Jorga A, Holt DW, Johnston A. Therapeutic drug monitoring of cyclosporine. Transplant Proc. 2004;36:396S-403S. (Pubitemid 38373898)
23. Midtvedt K. Therapeutic drug monitoring of cyclosporine. Transplant Proc. 2004;36:430S-3S. (Pubitemid 38373904)
24. Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther. 2002;72:209-219 (Pubitemid 35034499)
25. Pinto AG, Wang YH, Chalasani N, Skaar T, Kolwankar D, Gorski JC, et al. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin Pharmacol Ther. 2005;77:178-88. Ann Nucl Med (2010) 24:83-87 87 (Pubitemid 40269133)